Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with Stage I or Stage II non-small cell lung cancer that can be removed with surgery.
- People aged 18 to 80 years old.
- People whose heart and lung health is strong enough for lung removal surgery, as assessed by the operating surgeon.
- People with no previous history of cancer.
- People who have not received any treatment for their cancer before surgery (no pre-surgery chemotherapy or radiation).
- People who are well enough to carry out most daily activities (based on standard health scoring tools used by doctors).
- People whose blood test results meet these minimum levels: haemoglobin at or above 90 g/L, white blood cell count above 3 x 10⁹/L, and platelet count at or above 100 x 10⁹/L.
- People whose kidney function, measured by a blood marker called creatinine, is within an acceptable range.
- People who are able to give informed consent to participate.
Who may not be able to join:
- People who have received certain targeted cancer antibody treatments (cetuximab, panitumumab, or necitumumab) within the 60 days before the trial drug would be given.
- People who are pregnant or currently breastfeeding.
- People with a known history of allergic reactions to antibodies or products made from a specific type of cell used to manufacture biological medicines (NSO-derived products).
- People who have had a heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable chest pain within the 6 months before joining the trial.
- People currently taking certain heart rhythm medications, specifically Class IA drugs (such as quinidine or procainamide) or Class III drugs (such as dofetilide, amiodarone, or sotalol).
- People with a history or signs of scarring or inflammation in the lungs (interstitial pneumonitis or pulmonary fibrosis).
- People considered by the trial investigators to be unsuitable candidates for the study drug for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 306-966-12040
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1: Optimal dose of IRDye800CW-nimotuzumab for image guided surgery.; Phase 2: Determine the optimal time for IRDye800CW-nimotuzumab infusion for image guided surgery.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.